The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) is surging across India. Recent clinical data suggest that over 60% of some Indian populations suffer from this condition. Researchers are now focusing on how exosomal miR-122-3p MASLD pathways contribute to hepatic damage. Specifically, exosomes facilitate intercellular communication by carrying miRNAs that regulate metabolic genes. Consequently, these small vesicles serve as critical messengers in the progression of liver steatosis.

Mechanistic Insights: Exosomal miR-122-3p MASLD and FGFR4

Furthermore, a pivotal study recently identified that circulating exosomal miR-122-3p plays a causal role in MASLD. This microRNA specifically targets the 3'-untranslated region of Fibroblast Growth Factor Receptor 4 (FGFR4). When miR-122-3p levels rise, they significantly suppress FGFR4 expression in hepatocytes. Moreover, this impairment triggers a cascade of dysregulated lipid metabolism. Therefore, the loss of FGFR4 signaling serves as a primary driver for intracellular fat accumulation.

Impact on Lipid Synthesis and Oxidative Stress

The suppression of FGFR4 leads to the upregulation of key lipogenic regulators. Specifically, protein levels of SREBF1, FASN, and SCD1 increase markedly. These enzymes accelerate triglyceride accumulation, which eventually causes cellular damage. Additionally, elevated exosomal miR-122-3p levels correlate with increased reactive oxygen species (ROS) production. Importantly, this process also inhibits adenosine 5'-monophosphate-activated protein kinase (AMPK) activity. However, silencing miR-122-3p or overexpressing FGFR4 can effectively mitigate these pathological effects. Consequently, targeting this specific exosomal pathway offers a promising therapeutic strategy for MASLD management.

FAQs

How does exosomal miR-122-3p contribute to MASLD?

Exosomal miR-122-3p travels through the circulation and enters hepatocytes. Once inside, it suppresses the expression of FGFR4, which is vital for maintaining lipid homeostasis. This suppression leads to increased fat synthesis and liver damage.

Can targeting this pathway help treat fatty liver disease?

Yes, experimental models show that inhibiting miR-122-3p or restoring FGFR4 expression reduces triglyceride accumulation and oxidative stress. This suggests that the miR-122-3p/FGFR4 axis could be a viable target for future MASLD therapies.

Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Wang W et al. Effect of circulating exosomal miRNA-122-3p on metabolic dysfunction-associated steatotic liver disease through impairing FGFR4 expression. Chin Med J (Engl). 2026 Mar 16. doi: 10.1097/CM9.0000000000004003. PMID: 41839758.

Banerjee P et al. Prevalence of Metabolic Dysfunction-Associated Steatotic Liver Disease: Mapping Across Different Indian Populations (MAP Study). Diabetes Ther. 2025 May 17. doi: 10.1007/s13300-025-01754-w.

Xia & He Publishing. Mechanism of Metabolic Dysfunction-associated Steatotic Liver Disease: Important role of lipid metabolism. J Clin Transl Hepatol. 2024;12(8). doi: 10.14218/JCTH.2023.00392.